Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 5, 2026Cancer Research

Whole Genome Sequencing Identifies Genetic Alterations in Multiple Myeloma Immunotherapy Resistance

View Full Paper
Ask AI
Bookmark
Share

Authors

BPBruno PaivaPVPeter VoorheesPGPatricia T. Greipp

Discussion

Loading...

Member takes

Overview

GenoPredicta identifies genetic alterations in multiple myeloma, suggesting improved therapy selection and monitoring.

Key Points

  • This research aims to enhance the detection of genetic abnormalities in multiple myeloma to improve immunotherapy outcomes.
  • Developed GenoPredicta, a CLIA-approved clinical assay for whole genome sequencing.
  • Isolated circulating tumor cells from peripheral blood or tumor cells from bone marrow.
  • Utilized fluorescence-activated cell sorting and automated pipelines for rapid analysis.
  • Validated the assay against traditional fluorescence in situ hybridization methods.
  • Identified resistance-conferring alterations not detectable by traditional methods.
  • Observed biallelic loss of key therapeutic targets such as BCMA and GPRC5D.
  • Provided comprehensive genomic profiling from low-input samples, showing potential for broader oncology use.

Cite This Study

Paiva et al. (2026) studied this question.

synapsesocial.com/papers/69d1fca7a79560c99a0a2501https://doi.org/10.1158/1538-7445.am2026-1067
View Full Paper
Ask AI
Bookmark
Share